What have we learned from cancer immunotherapy in the last 3 years?
Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the development of novel treatments that can harness the p...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038596/ |
| id |
pubmed-4038596 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-40385962014-05-30 What have we learned from cancer immunotherapy in the last 3 years? Ascierto, Paolo A Marincola, Francesco M Commentary Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the development of novel treatments that can harness the patient’s immune system and prevent immune escape. Over the last few years, through numerous clinical trials and real-world experience, we have accumulated a large amount of evidence regarding the potential for long-term survival with immunotherapy agents in various types of malignancy. The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns. Furthermore, given the numerous immune checkpoints that exist and the multiple mechanisms used by tumours to escape the immune system, targeting distinct checkpoint pathways using combination approaches is an attractive therapeutic strategy with the potential to further enhance the antitumour immune response. BioMed Central 2014-05-21 /pmc/articles/PMC4038596/ /pubmed/24886164 http://dx.doi.org/10.1186/1479-5876-12-141 Text en Copyright © 2014 Ascierto and Marincola; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Ascierto, Paolo A Marincola, Francesco M |
| spellingShingle |
Ascierto, Paolo A Marincola, Francesco M What have we learned from cancer immunotherapy in the last 3 years? |
| author_facet |
Ascierto, Paolo A Marincola, Francesco M |
| author_sort |
Ascierto, Paolo A |
| title |
What have we learned from cancer immunotherapy in the last 3 years? |
| title_short |
What have we learned from cancer immunotherapy in the last 3 years? |
| title_full |
What have we learned from cancer immunotherapy in the last 3 years? |
| title_fullStr |
What have we learned from cancer immunotherapy in the last 3 years? |
| title_full_unstemmed |
What have we learned from cancer immunotherapy in the last 3 years? |
| title_sort |
what have we learned from cancer immunotherapy in the last 3 years? |
| description |
Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour immunology and enabled the development of novel treatments that can harness the patient’s immune system and prevent immune escape. Over the last few years, through numerous clinical trials and real-world experience, we have accumulated a large amount of evidence regarding the potential for long-term survival with immunotherapy agents in various types of malignancy. The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns. Furthermore, given the numerous immune checkpoints that exist and the multiple mechanisms used by tumours to escape the immune system, targeting distinct checkpoint pathways using combination approaches is an attractive therapeutic strategy with the potential to further enhance the antitumour immune response. |
| publisher |
BioMed Central |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038596/ |
| _version_ |
1612094583162798080 |